InvestorsHub Logo
Followers 66
Posts 11443
Boards Moderated 0
Alias Born 10/20/2009

Re: None

Wednesday, 02/22/2017 7:47:15 PM

Wednesday, February 22, 2017 7:47:15 PM

Post# of 345788
Ahhh..the good old days in 2015....have we come along any further????


Conclusions: Our pre-clinical results support the use of bavituximab as an immunomodulatory treatment in PD-1 sensitive and anti-PD-1 resistant/unresponsive tumors. This effect involves enhancing the activation of CD8+ TIL correlating with increased immune stimulatory components in the spleen and the tumor microenvironment.

http://meetinglibrary.asco.org/content/150815-156


I would hope so.....


wook

Best of $RESULTS for Humanity, FDA Approval(s), Partner(s) Production, Imaging and MOST IMPORTANTLY!!!
Research.
Always looking deeper. RIP Dr. Thorpe

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News